Stay updated with breaking news from Aik han goh. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ Reistone Biopharma (Reistone), a leading biotech company focused on development of innovative medicines for immune and inflammation diseases,. ....
Reistone Announces Positive Topline Phase 2 Results for SHR0302, a Selective JAK1 Inhibitor, for Treatment of Patients with Alopecia Areata finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Reistone Announces First Patient Dosed in Phase III Global Study in Atopic Dermatitis SHANGHAI, May 13, 2021 /PRNewswire/ Reistone Biopharma Company Limited (Reistone), a clinical stage biopharmaceutical company focused on developing novel medicines for autoimmune and inflammatory diseases, today announced the first patient has been dosed in their Phase III, global clinical trial (RSJ10333) of SHR0302, a potent and highly selective small molecule inhibitor of Janus kinase type 1 (JAK1) in patients with moderate-to-severe Atopic Dermatitis (AD). The trial is being conducted in Canada and China. The first patients enrolled were from Canada. RSJ10333 is a randomized, double-blinded, placebo-controlled study to evaluate efficacy and safety of oral SHR0302 in subjects aged 12 years and older with moderate to severe AD. A total of 330 adolescent and adult subjects will be enrolled and treated with 4 mg or 8 mg SHR0302, or Placebo for up to 52 weeks. Subjects taking the placebo ....